Browsing by Author De Ferrari, Gaetano M

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 2 of 2
Issue DateTitleAuthor(s)Citation
2017Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trialKeech, Anthony (Tony); De Ferrari, Gaetano M; Deedwania, Prakash; et al, Various; Giugliano, Robert P; Gouni-Berthold, Ioanna; Kuder, J; Leiter, Lawrence A.; Murphy, Sabina A.; Sabatine, Marc S.; Wiviott, S; NH&MRC Clinical Trials CentreCardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial, The Lancet Diabetes & Endocrinology, vol.5, 12, 2017,pp 941-950
2017Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trialKeech, Anthony (Tony); Ceska, Richard; De Ferrari, Gaetano M; et al, Various; Gaciong, Zbigniew A; Giugliano, Robert P; Gouni-Berthold, Ioanna; Lopez-Miranda, Jose; Park, Jeong-Gun; Pedersen, Terje R; Toth, Kalman; NH&MRC Clinical Trials CentreClinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial, The Lancet, vol.390, 10106, 2017,pp 1962-1971